67286 Federal Register / Vol. 83, No. 248 / Friday, December 28, 2018 / Notices 

1BHCs that are subsidiaries of a foreign banking 

organization are excluded from the definition of 

‘‘U.S. firm.’’ 

2The Board has stated that it will not take action 

to require bank holding companies or savings and 

loan holding companies with less than $100 billion 

in total consolidated assets to comply with certain 

existing regulatory requirements, including the 

requirements to report the 2052a. See Statement 

regarding the impact of the Economic Growth, 

Regulatory Relief, and Consumer Protection Act 

(July 6, 2018), available at https://

www.federalreserve.gov/newsevents/pressreleases/ 

files/bcreg20180706b1.pdf. Subsequently, the Board 

invited comment on a proposal that would more 

closely match the regulations for large banking 

organizations with their risk profiles, which 

included proposals that would affect the scope of 

application of the FR 2052a. The press release is 

available at https://www.federalreserve.gov/ 

newsevents/pressreleases/bcreg20181031a.htm. 

3See 83 FR 46163 (September 12, 2018). 

4See 83 FR 44451 (August 31, 2018). 

5See 12 CFR part 249.20. 

General description of report: The FR 

2052a is filed by U.S. bank holding 

companies (BHCs) and savings and loan 

holding companies (SLHCs) that are 

subject to the Liquidity Coverage Ratio 

rule (LCR rule) as a ‘‘covered depository 

institution holding company,’’ as 

defined in section 249.3 of the Board’s 

Regulation WW (12 CFR 249.3) 

(collectively, U.S. firms),1 with total 

consolidated assets of $50 billion or 

more and foreign banking organizations, 

as defined by section 211.21(o) of the 

Board’s Regulation K and including any 

U.S. bank holding company that is a 

subsidiary of a foreign banking 

organization (collectively, FBOs), with 

combined U.S. assets of $50 billion or 

more.2 Reporting frequency is based on 

the asset size of the firm and whether it 

has been identified as a firm supervised 

through the Large Institution 

Supervision Coordinating Committee of 

the Board. 

The FR 2052a is used to monitor the 

overall liquidity profile of certain 

institutions supervised by the Board. 

These data provide detailed information 

on the liquidity risks within different 

business lines (e.g., financing of 

securities positions, prime brokerage 

activities). In particular, these data serve 

as part of the Board’s supervisory 

surveillance program in its liquidity risk 

management area and provide timely 

information on firm-specific liquidity 

risks during periods of stress. Analyses 

of systemic and idiosyncratic liquidity 

risk issues are then used to inform the 

Board’s supervisory processes, 

including the preparation of analytical 

reports that detail funding 

vulnerabilities. 

Proposed revisions: On September 12, 

2018, the Board temporarily approved 3

certain revisions to the FR 2052a 

relating to the Economic, Growth, 

Regulatory Relief, and Consumer 

Protection Act (EGRRCPA) and Board’s 

related interim final rule amending the 

LCR Rule.4 As required by section 403 

of EGRRCPA, the Board amended the 

LCR rule within 90 days of the 

enactment of EGRRCPA to treat 

investment grade municipal obligations 

that are liquid and readily-marketable as 

level 2B HQLA for purposes of their 

liquidity regulations. Therefore, the 

Board temporarily revised the asset 

categories in the FR 2052a to enable 

institutions to report certain municipal 

obligations that meet all the 

requirements for inclusion as HQLA 

under section 20 of the LCR rule, as 

amended.5 Specifically, the Board 

amended the Assets Category Table in 

Appendix III of the FR 2052a such that 

the description of the asset classification 

code ‘‘IG2–Q’’ is sufficiently inclusive 

of municipal obligations that may 

qualify as HQLA under the LCR rule. 

The Board is now proposing to extend 

for three years these temporary revisions 

to the FR 2052a. 

Legal authorization and 

confidentiality: The FR 2052a report is 

authorized to be collected from BHCs 

pursuant to section 5(c) of the Bank 

Holding Company Act (‘‘BHC Act’’), 12 

U.S.C. 1844(c); from FBOs pursuant to 

section 8(a) of the International Banking 

Act, 12 U.S.C. 3106(a); from certain 

BHCs and FBOs pursuant to section 165 

of the Dodd-Frank Act, 12 U.S.C. 5365; 

and from SLHCs pursuant to section 

10(b)(2) and (g) of the Home Owners’ 

Loan Act (‘‘HOLA’’), 12 U.S.C. 

1467a(b)(2) and (g). Section 5(c) of the 

BHC Act authorizes the Board to require 

BHCs to submit reports to the Board 

regarding their financial condition, and 

section 8(a) of the International Banking 

Act subjects FBOs to the provisions of 

the BHC Act. Section 165 of the DoddFrank Act requires the Board to 

establish prudential standards, 

including liquidity requirements, for 

certain BHCs and FBOs. Section 10(g) of 

HOLA authorizes the Board to collect 

reports from SLHCs. The FR 2052a 

report is mandatory for covered 

institutions. 

The information required to be 

provided on the FR 2052a is collected 

as part of the Board’s supervisory 

process. Accordingly, such information 

is afforded confidential treatment under 

exemption 8 of the Freedom of 

Information Act (‘‘FOIA’’), which 

protects information from disclosure 

that is contained in or related to the 

examination or supervision of a 

financial institution. 5 U.S.C. 552(b)(8). 

In addition, the information may also be 

kept confidential under exemption 4 for 

the FOIA, which protects trade secrets 

or confidential commercial or financial 

information. 5 U.S.C. 552(b)(4). In 

limited circumstances, aggregate data 

for multiple respondents, which does 

not reveal the identity of any individual 

respondent, may be released. 

Consultation outside the agency: The 

Board consulted with other U.S. 

regulatory authorities, including the 

Office of the Comptroller of the 

Currency and Federal Deposit Insurance 

Corporation, in determining to propose 

revisions to the FR 2052a. 

Board of Governors of the Federal Reserve 

System, December 20, 2018. 

Michele Taylor Fennell, 

Assistant Secretary of the Board. 

[FR Doc. 2018–28204 Filed 12–27–18; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Office on Trafficking in Persons; 

Notice of Meeting 

AGENCY: Administration for Children 

and Families (ACF), Department of 

Health and Human Services. 

ACTION: Announcement of meeting. 

SUMMARY: Notice is hereby given, 

pursuant to the provisions of the 

Federal Advisory Committee Act 

(FACA) and the Preventing Sex 

Trafficking and Strengthening Families 

Act, that a meeting of the National 

Advisory Committee (NAC) on the Sex 

Trafficking of Children and Youth in the 

United States (Committee) will be held 

on January 9, 2019. The purpose of the 

meeting is for the Committee to finalize 

its outline of preliminary 

recommendations of best practices for 

States to follow in combating the sex 

trafficking of children and youth based 

on multidisciplinary research and 

promising, evidence-based models and 

programs. 

DATES: The meeting will be held on 

Thursday, January 9, 2019, from 1:00 

p.m. to 3:00 p.m. EST. 

ADDRESSES: The committee will 

convene virtually. 

To attend the meeting virtually, 

please register for this event online: 

https://www.acf.hhs.gov/otip/resource/ 

nacagenda0109. 

FOR FURTHER INFORMATION CONTACT: 

Katherine Chon, Director, Office on 

Trafficking in Persons, Designated 

Federal Officer (DFO) at 

EndTrafficking@acf.hhs.gov or (202) 

205–4554 or 330 C Street SW, 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 248 / Friday, December 28, 2018 / Notices 67287 

Washington, DC 20201. Additional 

information is available at https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

SUPPLEMENTARY INFORMATION: The 

formation and operation of the NAC are 

governed by the provisions of Public 

Law 92–463, as amended (5 U.S.C. App. 

2), which sets forth standards for the 

formation and use of federal advisory 

committees. 

Purpose of the NAC: The purpose of 

the NAC is to advise the Secretary and 

the Attorney General on practical and 

general policies concerning 

improvements to the nation’s response 

to the sex trafficking of children and 

youth in the United States. The NAC is 

established pursuant to Section 121 of 

the Preventing Sex Trafficking and 

Strengthening Families Act of 2014 

(Pub. L. 113–183). 

Tentative Agenda: The agenda can be 

found at https://www.acf.hhs.gov/otip/ 

partnerships/the-national-advisorycommittee. 

To submit written statements or RSVP 

to attend, email Ava.Donald@

acf.hhs.gov by January 2, 2019. Please 

include your name, organization, and 

phone number. More details on these 

options are below. 

Public Accessibility to the Meeting: 

Pursuant to 5 U.S.C. 552b and 41 CFR 

102–3.140 through 102–3.165, and 

subject to the availability of space, this 

meeting is open to the public. Seating is 

on a first to arrive basis. Security 

screening and a photo ID are required. 

The building is fully accessible to 

individuals with disabilities. Note: The 

January 9, 2019 meeting will only be 

held virtually. 

Written Comments or Statements: 

Pursuant to 41 CFR 102–3.105(j) and 

102–3.140 and section 10(a)(3) of the 

FACA, the public or interested 

organizations may submit written 

comments or statements to the NAC in 

response to the stated agenda of the 

meeting or in regard to the committee’s 

mission in general. Organizations with 

recommendations on best practices are 

encouraged to submit their comments or 

resources (hyperlinks preferred). 

Written comments or statements 

received after January 2, 2019 may not 

be provided to the Committee until its 

next meeting. 

Verbal Comments or Statements: 

Pursuant to 41 CFR 102–3.140d, the 

Committee is not obligated to allow a 

member of the public to speak or 

otherwise address the Committee during 

the meeting. Members of the public are 

invited to provide verbal statements 

during the Committee meeting only at 

the time and manner described in the 

agenda. The request to speak should 

include a brief statement of the subject 

matter to be addressed and should be 

relevant to the stated agenda of the 

meeting or the Committee’s mission in 

general. 

Minutes: The minutes of this meeting 

will be available for public review and 

copying within 90 days at: https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

Dated: December 20, 2018. 

Lynn A. Johnson, 

Acting Assistant Secretary for Children and 

Families. 

[FR Doc. 2018–28264 Filed 12–27–18; 8:45 am] 

BILLING CODE 4184–40–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–N–0536] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Medical Device 

User Fee Cover Sheet, Form FDA 3601 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on Form FDA 3601, 

entitled ‘‘Medical Device User Fee 

Cover Sheet,’’ which must be submitted 

along with certain medical device 

product applications, supplements, and 

fee payment of those applications. 

DATES: Submit either electronic or 

written comments on the collection of 

information by February 26, 2019. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before February 26, 

2019. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of February 26, 2019. 

Comments received by mail/hand 

delivery/courier (for written/paper 

submissions) will be considered timely 

if they are postmarked or the delivery 

service acceptance receipt is on or 

before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2012–N–0536 for ‘‘Agency Information 

Collection Activities; Proposed 

Collection; Comment Request; Medical 

Device User Fee Cover Sheet, Form FDA 

3601.’’ Received comments, those filed 

in a timely manner (see ADDRESSES), 

will be placed in the docket and, except 

for those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 


amozie on DSK3GDR082PROD with NOTICES1